 Tiziana Life Sciences PLC surged 19 to 73p after signing an exclusive licensing agreement with Precision BioSciences NASDAQ:DTIL. The pair will explore the use of Tizianas foralumab monoclonal antibody mAb to enhance the next generation of CAR-T therapies. 